Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy
Sponsor: Breast International Group
Listed as NCT00045032, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Breast International Group, it has been updated 9 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Feb 2017 — Jun 2017 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Nov 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Breast International Group
- ETOP IBCSG Partners Foundation
- European Organisation for Research and Treatment of Cancer - EORTC
- Hoffmann-La Roche
- NCIC Clinical Trials Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain, Aarau, Switzerland, Alba, Italy, Alzano Lombardo, Italy, Alzira, Spain, Antwerp, Belgium, Athens, Greece, Aviano, Italy, Bangkok, Thailand, Barcelona, Spain and 165 more location s